HR Execs on the Move

ICANotes

www.icanotes.com

 
ICANotes is a Asbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medical Profiles and Engineering

Medical Profiles & Engineering is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heartbeat Health

A new standard for virtual heart care. Heartbeat is a complete telehealth platform for cardiology that incorporates telemedicine, remote diagnostics, and digital heart health programs. Learn more

Ameriplan USA

How to make money Ameriplan and save on dental, vision, and prescription

Aid and Assist at Home

Aid and Assist at Home, Inc. is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.